PVR and neoplasm: For instance, the binding of TIGIT and CD155 can cause the CD155-expressing dendritic cells to be tolerogenic and reduce the production of cytokines IL-12 and IL-10; additionally, TIGIT can also inhibit the degranulation of NK cells, the production of cytokine, and NK cell-mediated tumor cytotoxicity [98].